The Second Affiliated Hospital of Guizhou Medical University, Guizhou Medical University, Guiyang, China.
The Clinical Medical College, Guizhou Medical University, Guiyang, China.
Technol Cancer Res Treat. 2024 Jan-Dec;23:15330338241271935. doi: 10.1177/15330338241271935.
Gastric cancer (GC) is a prevalent malignant tumor and ranks as the second leading cause of death among cancer patients worldwide. Due to its hidden nature and difficulty in detection, GC has a high incidence and poor prognosis. Traditional treatment methods such as systemic chemotherapy, radiotherapy, and surgical resection are commonly used, but they often fail to achieve satisfactory curative effects, resulting in a very low 5-year survival rate for GC patients. Currently, targeted therapy and immunotherapy are prominent areas of research both domestically and internationally. These methods hold promise for the treatment of GC. This article focuses on the signaling pathways associated with the development of GC, as well as the recent advancements and applications of targeted therapy and immunotherapy. The aim is to provide fresh insights for the clinical treatment of GC.
胃癌(GC)是一种常见的恶性肿瘤,在全球癌症患者死因中排名第二。由于其隐匿性和检测困难,GC 的发病率高,预后差。传统的治疗方法如全身化疗、放疗和手术切除等常用,但往往难以达到满意的疗效,导致 GC 患者的 5 年生存率非常低。目前,国内外靶向治疗和免疫治疗是研究的热点。这些方法为 GC 的治疗提供了希望。本文重点介绍了与 GC 发展相关的信号通路,以及靶向治疗和免疫治疗的最新进展和应用。旨在为 GC 的临床治疗提供新的思路。